Clinical advances for eczema and atopic dermatitis are transforming treatment opportunities and our knowledge of the disease more broadly. Explore the latest statistics and ongoing clinical advances.
Atopic Eczema patient organization leaders from eight countries worked together in defining the three most impactful policy drivers needed to establish atopic eczema as a priority amongst healthcare decision-makers.
The Economist Intelligence Unit
A report written by The Economist Intelligence Unit, and sponsored by Pfizer and the International Alliance of Dermatology Patient Organizations (GlobalSkin). It considers the healthcare system approaches and policy responses to the management of atopic dermatitis (AD), often referred to as atopic eczema
Allergy and Asthma Foundation of America
New U.S. research has found that even mild eczema can lower quality of life for sufferers and for some can cause an even more severe impact than other chronic illnesses including heart disease, diabetes and high blood pressure.
This paper seeks to identify the gaps and challenges in atopic dermatitis and to provide an incentive for the gathering of evidence and collaboration amongst stakeholders to positively impact quality of life for those living daily with AD.
Canadian Skin Patient Alliance
A national report of the patient and caregiver experience with atopic dermatitis.
Eczema Society of Canada
Eczema Society of Canada conducted online surveys of Canadians living with AD and had a total of 1,035 respondents from all provinces across Canada. The content of this report details the survey data collected from both the adult and children’s survey, and reflects the insights gathered through survey responses from Canadians impacted by AD.
Page 1 of 2